Format

Send to

Choose Destination
Ann Oncol. 2015 Apr;26(4):715-24. doi: 10.1093/annonc/mdv003. Epub 2015 Jan 16.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Author information

1
Abramson Cancer Center at the University of Pennsylvania, Philadelphia daniel.haller@uphs.upenn.edu.
2
National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh.
3
Department of Oncology, Florida Cancer Affiliates, Ocala, USA.
4
Leeds Institute of Cancer and Pathology and St James's University Hospital, Leeds, UK.
5
US Medical Affairs, Genentech, Inc., South San Francisco.
6
University of Pittsburgh Cancer Institute, Pittsburgh.
7
Tufts University School of Medicine, Boston.
8
Biostatistical Center and University of Pittsburgh Graduate School of Public Health Department of Biostatistics, Pittsburgh, USA.
9
University Clinic, Martin Luther University, Halle, Germany.

Abstract

BACKGROUND:

Adjuvant oxaliplatin plus capecitabine or leucovorin/5-fluorouracil (LV/5-FU) (XELOX/FOLFOX) is the standard of care for stage III colon cancer (CC); however, there is disagreement regarding oxaliplatin benefit in patients aged >70. In most analyses, the impact of medical comorbidity (MC) has not been assessed. Efficacy and safety of adjuvant XELOX/FOLFOX versus LV/5-FU were compared with respect to age and MC using pooled data from four randomized, controlled trials, selected for access to patient-level MC data and including commonly endorsed and utilized regimens.

PATIENTS AND METHODS:

Individual data from patients with stage III CC in NSABP C-08, XELOXA, X-ACT, and AVANT were pooled, excluding bevacizumab-treated patients. Patients were grouped by treatment, MC (low versus high), or age (<70 versus ≥70), and compared for disease-free survival (DFS), overall survival (OS), and adverse events (AEs). Multivariable Cox proportional hazards regression controlled for gender, T stage, and N stage.

RESULTS:

DFS benefits were shown for XELOX/FOLFOX versus LV/5-FU regardless of age or MC, although benefits were modestly attenuated for patients aged ≥70. Hazard ratios were 0.68 (P < 0.0001) and 0.77 (P < 0.014) for <70 and ≥70 age groups; 0.69 (P < 0.0001) and 0.59 (P < 0.0001) for Charlson Comorbidity Index ≤1 and >1 groups; and 0.70 (P < 0.0001) and 0.58 (P < 0.0001) for National Cancer Institute Combined Index ≤1 and >1 groups. OS was also significantly improved in all groups. Grade 3/4 serious AE rates were comparable across cohorts and MC scores and higher in patients aged ≥70. Oxaliplatin-relevant grade 3/4 AEs, including neuropathy, were comparable across ages and MC scores.

CONCLUSIONS:

Results further support consideration of XELOX or FOLFOX as standard treatment options for the adjuvant management of stage III CC in all age groups and in patients with comorbidities, consistent with those who were eligible for these clinical trials.

KEYWORDS:

adjuvant chemotherapy; age groups; capecitabine; colon cancer; comorbidity; oxaliplatin

PMID:
25595934
PMCID:
PMC4374386
DOI:
10.1093/annonc/mdv003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center